国产吉西他滨联合顺铂治疗晚期非小细胞肺癌的临床观察

目的 观察国产吉西他滨(GEM)联合顺铂(DDP)治疗晚期非小细胞肺癌的近期疗效、毒副反应、中位生存期及耐受性.方法 国产吉西他滨1 000 mg·m-2,静脉滴注30 min,第1、8 天;顺铂60～70 mg·m-2,静脉滴注,分3～ 4 d应用,28 d为一个周期,治疗39 例晚期非小细胞肺癌患者.结果 39 ...

Clinical research on combined chemotherapy of gemcitabine and cisplatin in the treatment of non-small cell lung cancer

Aim To evaluate the efficacy,side-effect,median survival duration and toxicity of gemcitabine（GEM）combined with cisplatin（DDP）in the treatment of advanced non-small-cell lung cancer.Methods Thirty-nine patients with advanced non-small-cell lung cancer were treated with gemcitabine 1000 mg·m-2 on d1、8,cisplatin 60～70 mg·m-2 on d1-3.The regimen was repeated every 28 days.All patients received two or more cycles.Results Thirty-nine patients were evaluated after 2 to 6 cycles of chemotherapy.None achieved CR and 15 cases achieved PR.The overall response rate（ORR）was 38.5% and the disease control rate（DCR）was 74.4%.The median time to progression（TTP）was 5.4 months,and median overall survival（OS）was 10.6 months.The most common toxicities were neutropenia,thrombocytopenia,anaemia and fatigue.These toxicities were well-tolerated.Conclusion Gemcitabine plus cisplatin is an effective and well tolerated regimen for non-small-cell lung cancer.